Autopsy report · NCT04561076

Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers

“Sponsor strategy”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Hengenix Biotech Inc

Sponsor type

Industry

Conditions

COVID 19

Interventions

HLX70; Placebo

Participants

0

Trials that died the same way

• Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients
  “sponsor strategy change” (92% match in meaning)
• POWER Study (Prospective Transbronchial Microwave + Robotic-Assisted Bronchoscopy)
  “Change in Sponsor strategy” (91% match in meaning)
• Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant
  “Strategic sponsor decision” (90% match in meaning)
• Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19
  “Sponsor's strategic decision” (89% match in meaning)
• Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness
  “Strategic decision of Sponsor” (89% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.